LONDON--(BUSINESS WIRE)--The Global Human Growth Hormone (HGH) Market is expected to grow at a CAGR of 4.22 percent from 2015-2019, in response to increased demand for HGH treatments, says research firm TechNavio.
HGH is approved for the treatment of various diseases like growth hormone deficiency, Noonan syndrome, and Turner syndrome, and for administration in children who are born small for gestational age.
About the Report
At present, HGH is generally administered via needle. However, this form of drug delivery is associated with poor patient compliance and injection-site associated reactions. In addition, needle-based drug delivery increases the risk of disease transmission.
The new report from TechNavio emphasizes the emergence of needle-free methods, which not only reduce the incidence of injection-site reactions or pain, but are also easy to self-administer. This ease of administration reduces the number of clinic/hospital visits, which results in increased patient compliance and increased efficacy of treatment.
“Various needle-free drug delivery devices are available in the market for delivering human growth hormones like cool.click 2, Tjet, Zomajet 2 Vision, Zomajet Vision X and SeroJet,” says Faisal Ghaus, Vice President of TechNavio.
“Many vendors are concentrating on developing and licensing needle-free drug delivery devices so as to launch new HGH delivery systems in the market.”
Key Information Covered in the Report:
- Market segmentation, size and forecast through 2019
-
Market Growth Drivers:
- Increase in Demand for Human Growth Hormone
- For a full detailed list, view our report.
-
Market Challenges:
- Intense Market Competition
- For a full detailed list, view our report.
-
Market Trends:
- Advances in Technology
- For a full detailed list, view our report.
-
Key Vendors:
- Merck Serono
- Novo Nordisk A/S
- Pfizer Inc.
-
Other Prominent Vendors:
- BioPartners
- Eli Lilly
- Ferring Pharmaceuticals
TechNavio currently has more than 3000 market research reports on a huge range of topics, including 50+ reports on hormone therapy:
If you are interested in more information, please contact our media team at media@technavio.com.
